Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | THPO | P40225 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40870 | 0.81 | LMNA (0.41) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL6424353 | 0.73 | CDA (0.45) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL288668 | 0.72 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL20459913 | 0.71 | LMNA (0.33) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL20833069 | 0.70 | CDA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6674416 | 0.70 | CDA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL17722383 | 0.69 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18503533 | 0.68 | LMNA (0.41) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL17440122 | 0.68 | CDA (0.41) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL18503534 | 0.68 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MTORTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594987-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | Hoser, Mark J. (GB) | 2005-11-16 | — | — | EP | claimed |
| WO-2004074503-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | HOSER MARK J (GB) | 2004-09-02 | — | — | WO | claimed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3981437-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3638215-A1 | RNA FORMULATIONS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3625246-A1 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | ModernaTX, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3458590-A1 | POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458105-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2641605-A1 | NOVEL POLYMER DERIVATIVE OF CYTIDINE METABOLISM ANTAGONIST | Nippon Kayaku Kabushiki Kaisha (JP) | 2013-09-25 | — | — | EP | disclosed |
| WO-2011079501-A1 | PRODRUG BASED ON CYTARABINE STRUCTURE AS WELL AS SYNTHESIZING METHOD AND APPLICATION THEREOF | 济南圣鲁金药物技术开发有限公司 (CN) | 2011-07-07 | — | — | WO | disclosed |
| CN-102115485-A | Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof | SANLUGEN PHARMATECH | 2011-07-06 | — | — | CN | disclosed |
| CN-101525361-B | Prodrug based on gemcitabine structure as well as synthesizing method and application thereof | JINAN SHENGLUJIN PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2010-11-17 | — | — | CN | disclosed |
| CN-101525361-A | Prodrug based on gemcitabine structure as well as synthesizing method and application thereof | SANLUGEN PHARMATECH DEV CO LTD | 2009-09-09 | — | — | CN | disclosed |
| CN-101490076-A | 3' -ethynylcytosine nucleoside derivatives | TAIHO PHARMACEUTICAL CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-1594987-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | Hoser, Mark J. (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074503-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | HOSER MARK J (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | LMNA 700/4885SMN1; SMN2 273/4885ALDH1A1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.